Loading…
Chinese pharmaceutical company making innovative oncology, diabetes and CNS drugs plus legacy generics.
Chinese pharmaceutical company making innovative oncology, diabetes and CNS drugs plus legacy generics.
Sells prescription drugs to Chinese hospitals through its own sales force, and many products depend on staying on the national reimbursement list, where prices are negotiated. Older generics have been squeezed by government bulk-buying tenders. Licensing fees and milestone payments from foreign partners add a second stream. Founder Zhong Huijuan is the controlling shareholder.
In one line: A mid-size Chinese Eli Lilly, generics-plus-innovation.
Moat: narrow (IP / patents, scale). Growing pipeline of homegrown innovative drugs licensed to multinational partners, alongside a large legacy generics base.
Headquarters: Lianyungang, China · Founded: 1995 · Employees: 9,347
Size Hansoh Pharma (3692.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $26.9B, the 59th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$34.80 on 6 Nov 2026.
Performance Over six months the shares fell 7.0%, against +7.9% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 25.0% over the last twelve months (peer median +15.6%); the operating margin is 37.6% (peer median 18.6%).
Valuation It trades at 27.5× forward earnings against a peer median of 16.8× (5th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -2 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 96.9 points above its cost of capital (7.8% WACC).
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$17.8B | HK$16.3B | HK$13.3B | HK$11.2B | HK$10.9B |
| Revenue growth | — | +23% | +19% | +2% | — |
| Gross profit | HK$16.1B | HK$14.7B | HK$12.1B | HK$10.0B | HK$9.90B |
| EBITDA | HK$7.13B | HK$6.30B | HK$4.72B | HK$3.40B | HK$3.50B |
| Net income | HK$7.50B | HK$6.03B | HK$4.74B | HK$3.62B | HK$3.00B |
| Free cash flow | HK$7.57B | HK$8.23B | HK$4.89B | HK$3.79B | HK$3.00B |
| Capital expenditure | HK$734M | HK$531M | HK$569M | HK$401M | HK$339M |
| Total debt | n/a | HK$117M | HK$125M | HK$4.79B | HK$5.01B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Hansoh Pharma 3692.HK | $26.9B | -7% | +25% | 38% | 27.5× | 8.9% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $49.7B | -6% | +6% | 27% | 36.4× | 14.9% |
| Innovent Biologics 1801.HK | $19.2B | -5% | +43% | 17% | 53.3× | 11.7% |
| Cspc Pharma 1093.HK | $12.4B | +5% | +25% | 28% | 9.3× | -10.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 3692.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.6% | +8.3% | 7th lowest of 21 |
| 6-month return | -7.0% | +7.9% | 3rd lowest of 21 |
| Distance from 52-week high | -20.8% | -10.0% | 7th lowest of 21 |
| Revenue growth (TTM) | +25.0% | +15.6% | 7th highest of 21 |
| Operating margin | 37.6% | 18.6% | 3rd highest of 21 |
| Forward P/E | 27.5× | 16.8× | 5th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 8.9% | 7.2% | 9th most demanding of 18 |
| Growth delivered (Del g) | +10.8% | +11.4% | 7th lowest of 18 |
| Hurdle (Req g minus delivered) | -1.9 pp | -9.9 pp | 9th most demanding of 18 |
| ROIC minus cost of capital | +96.9 pp | +2.0 pp | highest of 21 |
| EV / EBITDA | 24.2× | 15.7× | 7th most expensive of 18 |
| Net debt / EBITDA | -5.4× | 1.1× | 2nd least indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hansoh Pharma 3692.HK | Hong Kong | $26.9B | -7% | +25% | 38% | 27.5× | 8.9% | +10.8% |
| Roivant Sciences ROIV | United States | $28.1B | +36% | -68% | -18,146% | n/a | n/a | n/a |
| Astellas Pharma 4503.T | Japan | $28.2B | +11% | +19% | 23% | 11.6× | -11.0% | +11.4% |
| Insmed INSM | United States | $25.1B | -16% | +240% | -42% | n/a | n/a | n/a |
| Divi's Laboratories DIVISLAB.NS | India | $29.0B | +54% | +16% | 31% | 82.0× | 50.9% | +8.9% |
| Incyte INCY | United States | $24.4B | +21% | +25% | 12% | 15.4× | 14.2% | +14.0% |
| Viatris VTRS | United States | $22.9B | +17% | +5% | 10% | 7.5× | 12.5% | +3.7% |
| Daiichi Sankyo 4568.T | Japan | $31.9B | +7% | +17% | 13% | 18.6× | 7.2% | +17.1% |
| Sigma Healthcare SIG.AX | Australia | $22.4B | -1% | +209% | 9% | 37.1× | 28.2% | +26.1% |
| Zoetis ZTS | United States | $32.8B | -4% | +1% | 38% | 12.8× | -4.3% | +7.2% |
| Alnylam Pharmaceuticals ALNY | United States | $20.9B | -47% | +56% | 20% | 22.2× | 0.9% | +49.8% |
| Biogen BIIB | United States | $36.7B | +28% | +2% | 17% | 16.8× | 9.4% | -5.1% |
| Innovent Biologics 1801.HK | Hong Kong | $19.2B | -5% | +43% | 17% | 53.3× | 11.7% | +26.8% |
| Torrent Pharmaceuticals TORNTPHARM.NS | India | $19.1B | +9% | +42% | 22% | 72.2× | 37.9% | +11.3% |
| Otsuka Hldgs 4578.T | Japan | $38.6B | +2% | +11% | 18% | 16.3× | 0.4% | +11.7% |
| Royalty Pharma RPRX | United States | $38.8B | +33% | +11% | 66% | 11.3× | 9.9% | +2.3% |
| Haleon HLN.L | United Kingdom | $40.1B | +1% | +1% | 23% | 16.3× | 4.6% | +2.2% |
| Swedish Orphan Biovitrum SOBI.ST | Sweden | $17.6B | +13% | +15% | 30% | 25.5× | -1.1% | +13.1% |
| Exelixis EXEL | United States | $17.0B | +44% | +9% | 40% | 18.2× | -3.7% | +18.6% |
| Shionogi & 4507.T | Japan | $16.6B | -6% | +46% | 29% | 10.9× | -0.7% | +11.0% |
| Sichuan Biokin Pharmaceutical 688506.SS | China | $16.4B | -3% | +14% | -43% | n/a | n/a | n/a |